570 completed. 570 Phase 2, 113 Phase 1, 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 570 | Completed 570 |
| Phase 1 | 113 | Completed 113 |
| Phase 3 | 12 | Completed 12 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) Bomedemstat - Polycythemia Vera | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 20 | 2023-09-07 | 2026-05-07 |
| Venetoclax After TKI to Target Persisting Stem Cells in CML Venetoclax - Chronic Myeloid Leukemia | Phase 2 | Completed | Thomas Ernst, PD Dr. med. | 10 | 2023-08-31 | 2026-08-18 |
| Fedratinib in Combination With Nivolumab Fedratinib Oral Capsule [Inrebic], Nivolumab - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 30 | 2022-06-14 | 2026-04-08 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies Cyclophosphamide, Mesna, Filgrastim - Myeloid Malignancies, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2022-04-08 | 2025-12-19 |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation VIC- 1911 - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 16 | 2022-03-17 | 2025-12-22 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Fedratinib Pill - Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2022-03-01 | 2026-06-09 |
| A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera sapablursen - Phlebotomy Dependent Polycythemia Vera | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 50 | 2021-12-30 | 2026-07-09 |
| Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative flonoltinib 25mg, flonoltinib 100mg, flonoltinib 150mg - Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF | Phase 1 / Phase 2 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 31 | 2021-12-27 | 2025-10-01 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors asciminib, best available treatment - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Novartis Pharmaceuticals | 84 | 2021-12-06 | 2025-04-18 |
| Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. Jaktinib Hydrochloride Tablets - Myelofibrosis | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 34 | 2021-07-28 | 2023-11-03 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis PXS-5505 - Myelofibrosis, Primary Myelofibrosis (PMF) | Phase 1 / Phase 2 | Completed | Syntara | 43 | 2021-02-18 | 2026-08-04 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit PTG-300 - Polycythemia Vera | Phase 2 | Completed | Protagonist Therapeutics, Inc. | 20 | 2021-02-02 | 2024-03-18 |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Fludarabine, Bendamustine Hydrochloride, Busulfan - Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-01-21 | 2024-05-07 |
| Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm Diet intervention - Myeloproliferative Neoplasm | Phase 2 | Completed | University of California, Irvine | 28 | 2021-01-21 | 2022-06-22 |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies Bendamustine Hydrochloride, Cyclophosphamid - Myeloid Leukemia, Acute, Chronic Myeloid Leukemia | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-01-21 | 2024-10-15 |
| Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Ruxolitinib, Enasidenib - Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis | Phase 2 | Completed | John Mascarenhas | 6 | 2021-01-14 | 2025-02-04 |
Showing 20 of 570. Sign in to see all of them.
Leukemia, Myeloid, Acute (257) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228) · Leukemia (216) · Myelodysplastic Syndromes (205) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (197) · Primary Myelofibrosis (148) · Leukemia, Myeloid, Chronic-Phase (135) · Lymphoma, Non-Hodgkin (125) · Leukemia, Lymphocytic, Chronic, B-Cell (123) · Hodgkin Disease (118) · Blast Crisis (113) · Leukemia, Myeloid, Accelerated Phase (107) · Multiple Myeloma (104) · Congenital Abnormalities (100)
Hemic and Lymphatic Diseases (570) · Bone Marrow Diseases (563) · Hematologic Diseases (555) · Neoplasms (496) · Neoplasms by Histologic Type (463) · Leukemia, Myeloid (442) · Pathological Conditions, Signs and Symptoms (403) · Pathologic Processes (402) · Disease Attributes (400) · Chronic Disease (398) · Immune System Diseases (245) · Leukemia (244) · Immunoproliferative Disorders (232) · Lymphatic Diseases (230)
Cyclophosphamide (95) · fludarabine phosphate (93) · Busulfan (74) · Peripheral Blood Stem Cell Transplantation (74) · Mycophenolic Acid (67) · Cyclosporine (59) · Tacrolimus (59) · Whole-Body Irradiation (58) · Imatinib Mesylate (52) · Cytarabine (51) · Filgrastim (48) · Antilymphocyte Serum (47) · Methotrexate (45) · fludarabine (37) · Radiotherapy (35)
Fred Hutchinson Cancer Center (57) · M.D. Anderson Cancer Center (51) · National Cancer Institute (NCI) (38) · Memorial Sloan Kettering Cancer Center (22) · Novartis Pharmaceuticals (21) · National Heart, Lung, and Blood Institute (NHLBI) (17) · Bristol-Myers Squibb (14) · Case Comprehensive Cancer Center (14) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · City of Hope Medical Center (8) · Incyte Corporation (8) · Masonic Cancer Center, University of Minnesota (8) · Roswell Park Cancer Institute (8) · H. Lee Moffitt Cancer Center and Research Institute (7) · Gruppo Italiano Malattie EMatologiche dell'Adulto (6)
United States (451) · Italy (66) · Canada (50) · France (49) · Germany (47) · United Kingdom (40) · Australia (28) · South Korea (26) · Spain (26) · Belgium (21) · Japan (19) · Austria (17) · Israel (17) · Sweden (17) · Netherlands (15)
Brenda Sandmaier (11) · Jorge Cortes, MD (7) · John Mascarenhas, MD (6) · Ayalew Tefferi, MD (5) · Judith Karp (5) · Alessandro Rambaldi, MD (4) · B. Douglas Smith, MD (4) · Jorge E Cortes, MD (4) · Kyoo H. Lee, MD (4) · Martin S. Tallman, MD (4) · Michele Baccarani, MD (4) · Philip L. McCarthy, MD (4)
PMID 32499241, PMID 23524640, PMID 23065508, PMID 23620574, PMID 25361995, PMID 28835440, PMID 30885996, PMID 35235189, PMID 17715389, PMID 18997171, PMID 21403127, PMID 22133778, PMID 22430088, PMID 24383844, PMID 25527568, PMID 35007144, PMID 36054756, PMID 41758981, PMID 10204198, PMID 11331327, PMID 11468154, PMID 11585760, PMID 12750167, PMID 15339678, PMID 15514371, PMID 15817673, PMID 16115130, PMID 16275934, PMID 16670265, PMID 16709929, PMID 16775235, PMID 16990776, PMID 17146105, PMID 17162214, PMID 17910637, PMID 18048643, PMID 18203012, PMID 18245545, PMID 18327587, PMID 18451242, PMID 18650451, PMID 18769450, PMID 18838477, PMID 18989154, PMID 19167681, PMID 19179301, PMID 19211938, PMID 19286996, PMID 19289999, PMID 19451433
P30CA015704 (23), P30CA006973 (14), P01CA018029 (11), P30CA043703 (9), U01CA070095 (9), U10CA031946 (8), P01CA078902 (6), U10CA032102 (6), 2018 (5), P30CA033572 (5), 2005 (4), P01CA108671 (4), P30CA015083 (4), P30CA016672 (4), 2017 (3)